Natixis Advisors LLC Reduces Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Natixis Advisors LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 34.3% during the 4th quarter, Holdings Channel reports. The fund owned 1,022,142 shares of the company’s stock after selling 533,871 shares during the period. Natixis Advisors LLC’s holdings in Johnson & Johnson were worth $147,823,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Frank Rimerman Advisors LLC lifted its stake in shares of Johnson & Johnson by 0.3% in the 4th quarter. Frank Rimerman Advisors LLC now owns 35,942 shares of the company’s stock valued at $5,198,000 after purchasing an additional 100 shares during the period. Harbour Investment Management LLC lifted its stake in shares of Johnson & Johnson by 12.6% in the 4th quarter. Harbour Investment Management LLC now owns 5,123 shares of the company’s stock valued at $741,000 after purchasing an additional 575 shares during the period. Greykasell Wealth Strategies Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $395,000. Montis Financial LLC lifted its stake in shares of Johnson & Johnson by 7.3% in the 4th quarter. Montis Financial LLC now owns 4,500 shares of the company’s stock valued at $651,000 after purchasing an additional 308 shares during the period. Finally, Poinciana Advisors Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $1,739,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.0 %

Shares of JNJ opened at $162.94 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The firm has a 50-day moving average price of $154.98 and a 200 day moving average price of $156.37. The firm has a market capitalization of $392.29 billion, a P/E ratio of 24.50, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.29 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on JNJ shares. Leerink Partners decreased their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Bank of America upped their price objective on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 5th. Finally, Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.